Pinkerton Retirement Specialists LLC Makes New $190,000 Investment in Elanco Animal Health Incorporated (NYSE:ELAN)

Pinkerton Retirement Specialists LLC acquired a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 11,674 shares of the company’s stock, valued at approximately $190,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Jones Financial Companies Lllp acquired a new stake in shares of Elanco Animal Health in the 4th quarter valued at about $37,000. Tower Research Capital LLC TRC increased its holdings in shares of Elanco Animal Health by 169.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,212 shares of the company’s stock valued at $93,000 after acquiring an additional 3,906 shares in the last quarter. Capstone Investment Advisors LLC bought a new stake in shares of Elanco Animal Health during the first quarter valued at approximately $167,000. HBK Sorce Advisory LLC acquired a new position in shares of Elanco Animal Health during the fourth quarter worth approximately $169,000. Finally, Atomi Financial Group Inc. bought a new position in shares of Elanco Animal Health in the 1st quarter worth $180,000. 97.48% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ELAN has been the subject of a number of recent research reports. Piper Sandler decreased their price target on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research note on Monday, July 1st. Barclays decreased their target price on shares of Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Friday, June 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $17.57.

Elanco Animal Health Stock Performance

Elanco Animal Health stock traded down $0.15 during mid-day trading on Friday, reaching $12.72. 4,609,317 shares of the company’s stock were exchanged, compared to its average volume of 6,914,415. The firm has a market capitalization of $6.29 billion, a PE ratio of -4.80, a P/E/G ratio of 1.23 and a beta of 1.42. The company has a quick ratio of 1.96, a current ratio of 3.29 and a debt-to-equity ratio of 0.95. The business’s fifty day simple moving average is $16.30 and its 200 day simple moving average is $15.61. Elanco Animal Health Incorporated has a one year low of $8.52 and a one year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, May 8th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.08. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same period in the previous year, the business posted $0.45 EPS. The business’s revenue for the quarter was down 4.1% compared to the same quarter last year. On average, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.93 earnings per share for the current year.

Insider Buying and Selling

In other news, Director William F. Doyle acquired 15,000 shares of Elanco Animal Health stock in a transaction on Tuesday, May 21st. The stock was acquired at an average cost of $16.98 per share, with a total value of $254,700.00. Following the completion of the acquisition, the director now owns 76,330 shares in the company, valued at $1,296,083.40. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.57% of the stock is currently owned by insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.